TABLE 2.
Response to treatment—evaluable patients
| Classification | Aspergillus | Candida | Othera | Total |
|---|---|---|---|---|
| Overall | ||||
| Total no. of patients (%) | 16 (28) | 30 (52) | 12 (20) | 58 |
| Complete response | 3 | 17 | 6 | 26 |
| Partial response | 7 | 3 | 3 | 13 |
| Failed | 6 | 10 | 3 | 19 |
| By underlying disease or condition (complete or partial response/no. of patients) | ||||
| Hematologic malignancy | 4/6 | 6/7 | 4/4 | 14/17 |
| Solid tumor | 1/1 | 5/5 | 0/0 | 6/6 |
| Bone marrow transplant | 0/3 | 4/9 | 0/3 | 4/15 |
| Solid organ transplant | 2/3 | 2/2 | 1/1 | 5/6 |
| Otherb | 3/3 | 3/7 | 4/4 | 10/14 |
| Total | 10/16 | 20/30 | 9/12 | 39/58 |
| By neutrophil count (ANCc < 500 at baseline) | ||||
| Total no. of evaluable patients | 4 | 5 | 1 | 10 |
| Complete response | 1 | 2 | 1 | 4 |
| Partial response | 1 | 0 | 0 | 1 |
| Failed | 2 | 3 | 0 | 5 |
a
Histoplasma/Coccidioides, Cryptococcus, other molds, and other yeasts.
b
Other underlying diseases or conditions included human immunodeficiency virus infection, AIDS, chronic obstructive pulmonary disease, surgery, coagulopathy, diabetes mellitus, chronic granulomatous disease, sarcoid tumor, Crohn’s disease, anemia, hypertension, immunosuppression, prosthesis, thrombocytopenia, or none.
c
ANC, absolute neutrophil count.